Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 437

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 1036 locations
Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Status: Active
Location: 557 locations
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 398 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 197 locations
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Status: Active
Location: 174 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 158 locations
A Study Using Risk Factors to Determine Treatment for Children with Favorable Histology Wilms Tumors (FHWT)
Status: Active
Location: 157 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 144 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Status: Active
Location: 148 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Location: 409 locations
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Kidney Failure
Status: Active
Location: 125 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 116 locations
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Status: Active
Location: 107 locations
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Status: Active
Location: 112 locations
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Status: Active
Location: 114 locations
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Status: Active
Location: 81 locations
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Active
Location: 90 locations
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 94 locations
Adding Pirtobrutinib to the Usual Treatment for People with Newly Diagnosed Richter Transformation, The PIRAMID Trial
Status: Active
Location: 62 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 44 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 39 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 30 locations
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Status: Active
Location: 27 locations
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Status: Active
Location: 27 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 28 locations